Xencor Strengthens Antibody Therapeutics Patent Portfolio With Exclusive License From The University of Cambridge

Xencor, Inc. signed an agreement to exclusively license technology developed at the University of Cambridge that enables the creation of monoclonal antibodies with greatly enhanced potency. The technology includes specific Fc (antibody constant region) variants that complement Xencor’s proprietary suite of XmAb(TM) engineered Fc domains, which are designed to enhance the therapeutic properties of monoclonal antibodies. Xencor’s XmAb(TM) antibody Fc domains can be inserted into antibody candidates against any target antigen and may improve multiple important effector functions, including enhanced antibody-mediated tumor cell killing, sustained half-life and increased structural stability.

MORE ON THIS TOPIC